Ban of animal testing in Australia
Australia’s legislation regarding industrial chemicals has changed. Since July 1st 2020, animal testing information can no longer be used to prove safety of new cosmetic ingredients manufactured in or imported into Australia.

NEW AUSTRALIAN REGULATION AND PROHIBITION OF ANIMAL TESTING

In Australia, the National Industrial Chemicals Notification and Assessment Scheme (NICNAS) has been replaced in the beginning of July, 2020 by a new scheme known as Australian Industrial Chemicals Introduction Scheme (AICIS), as established by the Industrial Chemicals Act 2019 (IC Act 2019). AICIS is now the entity responsible for regulating the manufacture and importation of industrial chemicals, and consequently regulating cosmetic products. Chemicals are regulated depending on their use and if it is not for a therapeutic, agricultural, veterinary or food use, it is considered an industrial chemical.

Under Australian law, ‘new animal test data’ is defined as “any data obtained from tests conducted on cephalopod or any live vertebrate animal (other than human being) on or after 1 July 2020”.

According to the IC Act 2019, safety of new cosmetic ingredients manufactured or imported into Australia cannot be demonstrated with animal testing information. This means that the current legislation bans the use of new animal test data to support the introduction into Australia of industrial chemicals used exclusively as cosmetic ingredients. There are also restrictions on using new animal test data for chemicals with multiple end uses (including in cosmetics). Cosmetics industry and the Department of Health are working together to develop a voluntary code of practice.

Ingredients and cosmetics that are already on the market will not be affected by this new legislation. For new cosmetic ingredients, instead of animal testing, legislation allows the use of alternative methods to support its introduction (and safety), like the ones validated by the Organization for Economic Co-operation and Development (OECD) or computer-based modelling. Existing animal test data of a similar chemical can also be useful in the introduction of new chemicals and is overviewed in the legislation as an alternative also.  

Limited exception criteria, consistent with the European Union’s Regulation, have been set up regarding when new animal test data can be used for chemicals with an end use in cosmetics. The following exceptions apply where the new animal test data:

  • Shows that the chemical has a hazard characteristic and it conflicts with non-animal test data;
  • Is the only information that can demonstrate whether or not the chemical has a particular environment hazard characteristic;
  • Is from tests conducted on a different industrial chemical to the one that is being categorized or submitted an application for, and the company is not introducing that different chemical for an end use in cosmetics (read-across information from non-cosmetic chemicals);
  • The introduction has multiple end uses (including cosmetics), other exception criteria are not met and there is no alternative to animal test data.

All things considered, with the new Australian legislation, the ban of animal testing will cover most cosmetics introduced in Australia. Non-animal testing should be always considered first, and new animal test data should be faced as a last resort. Australian legislation allows for a range of alternative data sources to be provided instead of animal test data.

References:

  1. Australian Government, Department of Health – Australian Industrial Chemicals Introduction Scheme (AICIS) – website – https://www.industrialchemicals.gov.au/
  2. Australian Government – Industrial Chemicals (Notification and Assessment) Act 1989 (ICNA Act)
  3. Australian Government – Industrial Chemicals Act 2019
  4. Australian Industrial Chemicals Introduction Scheme (AICIS) – Industrial Chemicals Categorisation Guidelines
  5. Australian Industrial Chemicals Introduction Scheme (AICIS) – Industrial Chemicals Categorisation Guidelines – Final Draft, 2019
  6. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products –

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »